Redefining the role(s) of endothelial αvβ3-integrin in angiogenesis

Abstract excerpt

For nearly two decades now, the RGD (Arg-Gly-Asp)-binding αvβ3-integrin has been a focus of anti-angiogenic drug design. These inhibitors are well-tolerated, but have shown only limited success in patients. Over the years, studies in β3-integrin-knockout mice have shed some light on possible explanations for disappointing clinical outcomes. However, studying angiogenesis in β3-integrin-knockout mice is a blunt...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis and VEGF in Cancer
• Share to Cell Adhesion Molecules Research
• Share to Platelet Disorders and Treatments